Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haoxi Health Technology (HAO) Total Non-Current Liabilities (2023 - 2025)

Haoxi Health Technology's Total Non-Current Liabilities history spans 3 years, with the latest figure at $266048.0 for Q4 2025.

  • Quarterly Total Non-Current Liabilities rose 768.9% to $266048.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $266048.0 through Dec 2025, up 768.9% year-over-year, with the annual reading at $333819.0 for FY2025, 9.3% down from the prior year.
  • Total Non-Current Liabilities came in at $266048.0 for Q4 2025, down from $333819.0 in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $368043.0 in Q2 2024 to a low of $30619.0 in Q4 2024.
  • The 3-year median for Total Non-Current Liabilities is $321211.0 (2023), against an average of $263948.0.
  • The largest YoY upside for Total Non-Current Liabilities was 768.9% in 2025 against a maximum downside of 9.3% in 2025.
  • Haoxi Health Technology's Total Non-Current Liabilities stood at $321211.0 in 2023, then crashed by 90.47% to $30619.0 in 2024, then surged by 768.9% to $266048.0 in 2025.
  • Per Business Quant, the three most recent readings for HAO's Total Non-Current Liabilities are $266048.0 (Q4 2025), $333819.0 (Q2 2025), and $30619.0 (Q4 2024).